Drug Interactions between Alecensa and Lorbrena
This report displays the potential drug interactions for the following 2 drugs:
- Alecensa (alectinib)
- Lorbrena (lorlatinib)
Interactions between your drugs
No interactions were found between Alecensa and Lorbrena. However, this does not necessarily mean no interactions exist. Always consult your healthcare provider.
Alecensa
A total of 100 drugs are known to interact with Alecensa.
- Alecensa is in the drug class multikinase inhibitors.
- Alecensa is used to treat Non Small Cell Lung Cancer.
Lorbrena
A total of 511 drugs are known to interact with Lorbrena.
- Lorbrena is in the drug class multikinase inhibitors.
- Lorbrena is used to treat Non Small Cell Lung Cancer.
Drug and food interactions
lorlatinib food
Applies to: Lorbrena (lorlatinib)
Do not consume grapefruit or grapefruit juice during treatment with lorlatinib. Grapefruit juice can significantly increase the blood levels and effects of lorlatinib, which may result in a greater risk of side effects. Your doctor may be able to prescribe alternatives that do not interact, or you may need a dose adjustment or more frequent monitoring to safely use both. Talk to your doctor if you have any questions or concerns. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
alectinib food
Applies to: Alecensa (alectinib)
Food significantly increases the absorption of alectinib. You should take each dose of alectinib with food. Taking it on an empty stomach may lead to inadequate blood levels and reduced effectiveness of the medication.
Therapeutic duplication warnings
Therapeutic duplication is the use of more than one medicine from the same drug category or therapeutic class to treat the same condition. This can be intentional in cases where drugs with similar actions are used together for demonstrated therapeutic benefit. It can also be unintentional in cases where a patient has been treated by more than one doctor, or had prescriptions filled at more than one pharmacy, and can have potentially adverse consequences.
Multikinase inhibitors
Therapeutic duplication
The recommended maximum number of medicines in the 'multikinase inhibitors' category to be taken concurrently is usually one. Your list includes two medicines belonging to the 'multikinase inhibitors' category:
- Alecensa (alectinib)
- Lorbrena (lorlatinib)
Note: In certain circumstances, the benefits of taking this combination of drugs may outweigh any risks. Always consult your healthcare provider before making changes to your medications or dosage.
See also
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.